应用联合减压术治疗中晚期脑疝疗效观察

目的　观察联合减压术治疗特重型颅脑损伤合并嵌顿性脑疝的效果。方法　将 97例格拉斯哥昏迷评分 (GCS) 3～ 5分的特重型颅脑损伤合并嵌顿性脑疝患者随机分为两组 ,分别采用联合减压术 (46例 )与常规骨瓣开颅术 (5 1例 )治疗 ,术后两组均经常规治疗。随访 1～ 32个月 ,平均 7个月。比较两组患者临床疗效、颅内压变化及并发症发生率。结果　联合减压治疗组有效率为 80 .4 % (37/ 4 6例 ) ,其中恢复良好、中残2 7例 (占 5 8.7% ) ,重残 10例 (占 2 1.7% ) ,死亡 9例 (占 19.6 % ) ;常规骨瓣开颅术对照组有效率为 33.4 %(17/ 5 1例 ) ,其中恢复良好、中残 6例 (占 11.8% ) ,重残 11例 (占 2 1.6 % ) ,死亡 34例 (占 6 6 .6 % ) ,两组有效率和病死率比较差异均有显著性 (P均 <0 .0 1)。联合减压治疗组患者颅内压下降速度和程度优于常规骨瓣开颅术对照组 (P<0 .0 5 )。联合减压治疗组患者的急性脑膨出、切口疝、切口脑脊液漏、外伤性癫疒间及术后枕叶脑梗死发生率均明显低于常规骨瓣开颅术对照组 (P<0 .0 5或 P<0 .0 1) ,但两组术后颅内感染发生率差异无显著性 (P>0 .0 5 )。结论　联合减压术治疗特重脑损伤合并嵌顿性脑疝患者的疗效优于常规骨瓣开颅术。     

SARS相关冠状病毒S1融合蛋白的原核表达与纯化

目的：克隆严重急性呼吸综合征相关冠状病毒(SARS-CoV)S1蛋白编码DNA，构建原核表达质粒pGEX-5T／S1，并诱导表达谷胱甘肽巯基转移酶融合蛋白。方法：采用PCR方法扩增合成S1片段，并克隆入载体中，经双酶切鉴定和测序后把S1序列定向插入原核表达载体pGEX-5T的多克隆位点，转化大肠杆菌K802，将纯化后的融合蛋白用于SARS—CoV抗体阳性血清的检测。结果：GST—S1融合蛋白以可溶形式表达，纯化后的蛋白用ELISA法检测，结果与对照相符。结论：成功诱导原核表达并纬化出融合蛋白S1，为将其应用于SARS—CoV的特异性检测和亚单位疫苗研究奠定了基础。     

治疗老年重症呼吸衰竭42例临床分析

目的：探讨机械通气联合支气管肺泡灌洗（BAL）在治疗老年重症呼吸衰竭的作用。方法：选择常规治疗后病情无缓解的重症老年呼吸衰竭患者42例。建立人工气道行钡械通气治疗12～24h后，低氧血症纠正不理想，气道压力偏高，痰多者，应用加温至37℃生理盐水加庆大霉素、地塞米松及爱全乐经纤支镜行BAL，吸除呼吸道粘稠分泌物，每日一次，连续3—5天。结果：42例患者中，37例通气24h，经支气管肺泡灌洗后，气道压力下降，临床症状好转，缺氧及二氧化碳滞留得到改善，病原菌得到明确，成功脱机出院。结论：对老年重症呼吸衰竭在机械通气的基础上联合支气管肺泡灌洗是治疗呼吸衰竭安全有效的重要措施，值得临床应用。     

重型颅脑损伤开颅术中急性脑膨出的防治

目的探讨重型颅脑损伤开颅术中急性脑膨出的原因及对策。方法对120例重型颅脑损伤开颅术中急性脑膨出的原因、对策及预后进行回顾性分析。结果（1）迟发血肿65例，其中同侧脑内血肿10例，硬膜外血肿8例，对侧硬膜外血肿21例，硬膜下血肿10例，脑内血肿9例，大脑纵裂血肿7例；（2）急性弥漫性脑肿胀40例；（3）外伤性大面积脑梗死15例；（4）复合伤患者有30例。合并胸部、腹部及四肢骨折，有明显的低血压和低血氧症状；（5）术中操作不当，误诊误治10例。结论重型颅脑损伤开颅术中急性脑膨出的主要原因有迟发性颅内血肿，弥漫性脑肿胀，严重脑水肿，广泛脑梗死，术中操作不当，对病情的误诊误治，麻醉问题等。根据不同的原因进行正确处理，可以降低急性脑膨出的重残率及病死率。     

复杂性严重胰腺外伤的外科综合治疗

目的 探讨复杂性严重胰腺外伤的抢救和治疗.方法 本组12例患者采取外科手术、胃造瘘和空肠造瘘、腹腔置管冲洗、深静脉高营养等综合治疗.结果 抢救成功10例,死亡2例.结论 复杂性重度胰腺外伤的患者,准确判断伤情,不断调整治疗方案;选择合理的手术方式和手术时机,胃造瘘和空肠造瘘,深静脉高营养是治疗的关键,胰周的通畅引流和灌洗是抢救治疗成功保证.     

急性重症胰腺炎的治疗:证据、争议与反思

急性重症胰腺炎的治疗和研究近年来已经出现了一些新的变化。本文综述了循证医学分析的一些结论和研究的热点及争议，对急性重症胰腺炎的治疗思路提出反思。     

A randomized pilot study in Type 1 diabetes complicated by severe hypoglycaemia, comparing rigorous hypoglycaemia avoidance with insulin analogue therapy, CSII or education alone.

AIM: To determine potential for amelioration of recurrent severe hypoglycaemia without worsening in overall control in individuals with long-standing Type 1 diabetes (T1DM). METHODS: Twenty-one people with T1DM characterized by altered hypoglycaemia awareness and debilitating severe hypoglycaemia were randomized in a pilot 24-week prospective study to optimized analogue therapy (ANALOGUE; lispro/glargine); continuous subcutaneous insulin infusion therapy (CSII; lispro); or re-education with relaxation of blood glucose targets on existing conventional insulin regimen (EDUCATION). Glycaemic profiles and duration of biochemical hypoglycaemia were measured by continuous subcutaneous glucose monitoring and self-monitored blood glucose. RESULTS: Further severe hypoglycaemia was prevented in five participants (71%) in each group (P = 0.06). Incidence of severe hypoglycaemia was: 0.6 (ANALOGUE), 0.9 (CSII), and 3.7 (EDUCATION) episodes per patient year. Restoration of hypoglycaemia awareness was confirmed by validated questionnaire in three (43%) ANALOGUE, four (57%) CSII and five (71%) EDUCATION patients. Glycated haemoglobin (HbA1c) was significantly improved in the ANALOGUE group between weeks 0 and 24 (8.6 +/- 1.1 vs. 7.6 +/- 0.8%; P = 0.04 for change). Non-significant improvement was seen in the CSII group (8.5 +/- 1.9 vs. 7.4 +/- 1.0%; P = 0.06). No change in HbA1c was seen in the EDUCATION group (8.5 +/- 1.1 vs. 8.3 +/- 1.0%; P = 0.54). There were no episodes of diabetic ketoacidosis or any other adverse events in any group. CONCLUSIONS: In this pilot randomized trial comparing optimized ANALOGUE, CSII or EDUCATION alone in unselected individuals with recurrent severe hypoglycaemia, we show potential for restoring hypoglycaemia awareness and preventing further severe hypoglycaemia with concomitant improvement in glycaemic control in ANALOGUE and CSII groups.     

Osteoporosis in severe congenital neutropenia treated with granulocyte colony-stimulating factor

Recombinant human granulocyte colony-stimulating factor (G-CSF) has substantially improved life expectancy for children with severe congenital neutropenia (SCN). Severe osteoporosis, reported in this population, may relate to the disease process, or be a therapeutic side-effect. This report details bone loss, quantitated absorptiometrically and histomorphometrically, in a child with SCN and vertebral collapse, and the positive response to anabolic steroid and bisphosphonate therapy.     

Minor,moderate and severe head injury

Summary The future role of the neurosurgeon in the management of head injury is reviewed in terms of the care of patients with minor, moderate and severe head injuries. In minor head injury it is predicted that there will be increasing pressure on the neurosurgeon to undertake the management and follow-up of all patients who have sustained head injury, and this will place a considerable additional load on each neurosurgical unit. This is based on a survey of 1919 head injuries admitted in one calendar year (1981), consisting of 93 severe injuries (GCS < 8), 210 moderate injuries (GCS 8–12), and 1616 minor injuries (GCS 13/14). In moderate injuries CT will assume a major role in detecting hematoma early and identifying contusions. There may yet be a role for steroids in these cases and there should be a greater use of neurorehabilitation, instead of the current overemphasis on the severely injured. In severe injury future efforts will be to prevent early secondary insults and to find better methods of controlling raised intracranial pressure.